Subgroup analyses of VELOUR and RAISE trials suggest a potential benefit of the addition of anti-angiogenics in patients with BRAF-mutant CRC, although results were restricted by the small sample size [15,16]. This evidence concerns the gene BRAF and colorectal carcinoma.